The Nasdaq Composite Index has nearly doubled since the end of 2011, led by its riskiest sector: biotechnology.But biotech companies vary more than most in other industries. Some have no hopes of ever making money. And others are backed by products that are established in the marketplace and are quite profitable.The Nasdaq Biotechnology Index NBI, +0.40% has risen 227% since […]
View photo.Biotechnology ETFs have leapt out of the gate in 2015 with another strong spurt of momentum that has catapulted them to the top of sector rankings. The unequivocal asset leader in this category is the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), which has more than $8 billion under management.IBB has gained more than 12 percent so far this […]
Source: Celgene CorporationIt’s been proven time and time again that investing for the long haul outperforms short-term trading, but biotechnology stock investors must also realize that the industry moves so quickly that only the best-of-breed players ought to be stashed away for the long term. For that reason, while I’m happy to own a few speculative biotech stocks here and […]
You may have already been aware that the biotechnology sector has been hot over the past several years. But have you seen it lately? While most other sectors have been trending sideways, or even down as in the case of energy, the biotechnology sector has been absolutely on fire – with the largest biotech ETF iShares Nasdaq Biotechnology (NASDAQ: IBB) […]
Biotech stocks can often make big moves after reporting trial data, but it’s FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they’re most excited about. Read on to learn which three companies and drugs are on their radar.Source: Celgene Corporation.: […]
View photo.By and large, short interest among the leading biotechs and emerging pharmaceuticals dwindled between the January 15 and January 30 settlement dates.Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).Here we take a quick look at how these three stocks have fared recently and what analysts expect from them. That […]
Under agreement with StreetWise Reports, I’m pleased to share their recent coverage of the regenerative medicine sector.Original Source: Source: Peter Byrne of The Life Sciences Report (1/22/15)”Convert Catalysts into Profits: Sagient Research’s Edward Stopke“The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline […]
View gallery.Biotech is big, and the industry has been big for quite some time.As a matter of fact, biotechnology has been the second-best performing industry over the last two years.Biotech stocks obviously come in all different shapes and sizes. Some investors like the small-caps, others prefer the middle of the road mid-caps.However, at the end of the day, the big […]
This week Jim Cramer has been highlighting the hottest biotech stocks for 2015 as a part of his series “Biotech, the Next Generation.”One of the best performing biotechs for 2014 was the orphan drug company PTC Therapeutics, which rallied 205 percent last year. Shire PLC recently acquired NPS Pharmaceuticals at a 51 percent premium to where it was trading before.This […]
What Investors Are Looking At In The Stem Cell Sector
By iCELL News on January 14, 2015 · Sector
Stem cell stocks did poorly in 2014.However, many of these companies have catalysts in the first quarter of 2015 that could bring attention to the sector.In anticipation of a Phase 2 clinical update, Brainstorm Cell Therapeutics IncBCLI 1.89%stock rallied nearly 100 percent. The […]
